



Form PTO-1449 (modified) U.S. Patent and Trademark Office Information Disclosure Statement (Use several sheets if necessary)		Atty. Docket No. UTSC:664	Serial No. 09/599,152
		Applicant David Yang <i>et al.</i>	
		Filing Date: June 21, 2000	Group: 1616
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A46	4,279,992	7/21/81	Boguslaski <i>et al.</i>	435	7	10/23/79
	A47	4,789,542	12/06/88	Goodman and Knapp, Jr.	424	1.1	4/29/86
	A48	4,824,659	4/25/89	Hawthorne	424	1.1	6/07/85
	A49	5,013,556	5/07/91	Woodle <i>et al.</i>	424	450	10/20/89
	A50	5,356,793	10/18/94	Koezuka <i>et al.</i>	435	32	2/01/91
	A51	5,643,883	6/01/97	Marchase and Darbha	514	23	1/19/95
	A52	5,688,487	11/18/97	Linder <i>et al.</i>	424	1.65	6/06/95
	A53	5,834,266	11/10/98	Crabtree <i>et al.</i>	435	172.3	8/18/94
	A54	5,877,289	3/02/99	Thorpe and Edgington	530	387.1	6/07/95
	A55	5,891,468	4/06/99	Martin and Zalipsky	424	450	10/10/97
	A56	6,033,884	3/07/00	Woo <i>et al.</i>	435	172.3	12/14/93
	A57	6,054,436	4/25/00	Crabtree <i>et al.</i>	514	31	5/29/98

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B11	WO 98/08859	3/05/98	WIPO			English

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C342	Boersma <i>et al.</i> , "Quantification of apoptotic cells with fluorescein isothiocyanate-labeled annexin V in Chinese hamster ovary cell cultures treated with cisplatin," <i>Cytometry</i> , 24:123-130, 1996.
	C343	Cafaggi <i>et al.</i> , "Synthesis and antitumor activity of a new cis-diammineplatinum (III) complex containing procaine hydrochloride," <i>Anticancer Research</i> , 12:2285-2292, 1992.

25485041.1

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)		Atty. Docket No. UTSC:664	Serial No. 09/599,152
List of Patents and Publications for Applicant's		Applicant David Yang <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Filing Date: June 21, 2000	Group: 1616
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	


### **Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C344	Cammisuli <i>et al.</i> , "SDZ 281-977: a modified partial structure of lavendustin A that exerts potent and selective antiproliferative activities in vitro and in vivo," <i>Int J Cancer</i> , 65:351-359, 1996.
	C345	Chakrabarti <i>et al.</i> , "Interaction of the antitumor antibiotic chromomycin A3 with glutathione, a sulphydryl agent, and the effect upon its DNA binding properties," <i>Biochemical Pharmacology</i> , 56:1471-1479, 1998.
	C346	Connors, "Anticancer drug development: the way forward," <i>The Oncologist</i> , 1:180-181, 1996.
	C347	Guo and Gallo, "Selective protection of 2', 2'-difluorodeoxycytidine (Gemcitabine)," <i>J Org Chem</i> , 64:8319-8322, 1999.
	C348	Hirsch <i>et al.</i> , "PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection," <i>Experimental Cell Research</i> , 241:426-434, 1998.
	C349	Hjarnaa <i>et al.</i> , "CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo," <i>Cancer Res.</i> , 59:5751-5757, 1999.
	C350	Inoue <i>et al.</i> , "Evaluation of In-111 DTPA-paclitaxel scintigraphy to predict response on murine tumors to paclitaxel," <i>Annals of Nuclear Medicine</i> , 13(3):169-174, 1999.
	C351	Jiang <i>et al.</i> , "Antitumor activity of didemnin B in the human tumor stem cell assay," <i>Cancer Chemother Pharmacol</i> , 11:1-4, 1983.
	C352	Jiang <i>et al.</i> , "3-(Iodoacetamido)-benzoylurea: a novel cancercidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells," <i>Cancer Res.</i> , 58:5389-5395, 1998.
	C353	LeClerc and Cedergren, "Modeling RNA-ligand interactions: the rev-binding element RNA-aminoglycoside complex," <i>J Med Chem</i> , 41:175-182, 1998.
	C354	Lundberg <i>et al.</i> , "Conjugation of an anti-B-cell lymphoma monoclonal antibody, LL2, to long-circulating drug-carrier lipid emulsions," <i>J Pharm Pharmacol</i> , 51:1099-1105, 1999.
	C355	McGahon <i>et al.</i> , "Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system," <i>British Journal of Haematology</i> , 101:539-547, 1998.
	C356	Meyer <i>et al.</i> , "Tryptophan hydrolase antibodies used in the diagnosis of carcinoid," <i>Hepato-Gastroenterology</i> , 45:1522-1526, 1998.

25485041.1

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No. UTSC:664	Serial No. 09/599,152	
<b>Applicant</b> <b>David Yang et al.</b>		
Filing Date: June 21, 2000	Group: 1616	
<b>U.S. Patent Documents</b> <i>See Page 1</i>	<b>Foreign Patent Documents</b> <i>See Page 1</i>	<b>Other Art</b> <i>See Page 1</i>

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C357	Murray <i>et al.</i> , "Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer," <i>Journal of Pathology</i> , 185:256-261, 1998.
	C358	Palyi <i>et al.</i> , "Effects of methylacetylenic putrescine, and ornithine decarboxylase inhibitor and potential novel anticancer agent, on human and mouse cancer cell lines," <i>Anti-Cancer Drugs</i> , 10:103-111, 1999.
	C359	Pavicevic <i>et al.</i> , "Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer," <i>Coll Antropol</i> , 22(2):629-635, 1998.
	C360	Pavlik <i>et al.</i> , "Properties of anticancer agents relevant to in vitro determinations of human tumor cell sensitivity," <i>Cancer Chemother Pharmacol</i> , 11:8-15, 1983.
	C361	Rasey <i>et al.</i> , "Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia," <i>Int J Radiation Oncology Biol Phys</i> , 17:985-991, 1989.
	C362	Rasey <i>et al.</i> , "Characteristics of the binding of labeled fluoromisonidazole in cells in vitro," <i>Radiation Research</i> , 122:301-308, 1990.
	C363	Reutelingsperger and van Heerde, "Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis," <i>Cell Mol Life Sci</i> , 53:527-532, 1997.
	C364	Thompson, "Apoptosis in the pathogenesis and treatment of disease," <i>Science</i> , 267:1456-1462, 1995.
	C365	Tolomeo <i>et al.</i> , "The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis," <i>Cell Death and Differentiation</i> , 5:735-742, 1998.
	C366	Van den Eijnde <i>et al.</i> , "In situ detection of apoptosis during embryogenesis with annexin V: from whole mount to ultrastructure," <i>Cytometry</i> , 29:313-320, 1997.
	C367	Wright <i>et al.</i> , "Aminoglycoside antibiotics: structures, functions, and resistance," In: <i>Resolving the Antibiotic Paradox</i> , Rosen and Mobashery eds, Kluwer Academic/Plenum Pub NY, 1998.
	C368	Yoshinari <i>et al.</i> , "Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I," <i>Cancer Res.</i> , 59:4271-4275, 1999.

25485041.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.